Can you provide the average price target for SURGEPAYS INC stock?
8 analysts have analysed SURG and the average price target is 9.95 USD. This implies a price increase of 1077.2% is expected in the next year compared to the current price of 0.8448.
SURGEPAYS INC (SURG) Forecast, Price Target & Analyst Ratings
NASDAQ:SURG • US86882L2043
Current stock price
0.8448 USD
-0.02 (-1.77%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SURGEPAYS INC (SURG).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 23, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.16
- Revenue Estimate
- 21.58M
Price Target Details & History
Consensus Price Target and Range
Mean target
$9.95
Upside
+ 1,077.20%
From current price of $0.84 to mean target of $9.95, Based on 8 analyst forecasts
Low
$9.85
Median
$9.95
High
$10.24
Price Target Revisions
1 Month
0.00%
3 Months
2.63%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for SURG. The average price target is 9.95 USD. This implies a price increase of 1077.2% is expected in the next year compared to the current price of 0.8448.
The average price target has been revised upward by 2.63% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
SURG was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about SURG.
In the previous month the buy percentage consensus was at a similar level.
SURG was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-22 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-10-03 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-06-16 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-04-22 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-12-16 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-09-11 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-06-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-04-01 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-03-13 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-02-28 | Maxim Group | Initiate | Buy |
| 2022-01-24 | Ascendiant Capital | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 23, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.16
- Revenue Estimate
- 21.58M
- Revenue Q2Q
- 124.86%
- EPS Q2Q
- 84.00%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-18.49%
EPS (1 Month)
0.00%
EPS (3 Months)
-633.33%
Next Earnings Summary
SURG is expected to report earnings on 3/23/2026. The consensus EPS estimate for the next earnings is -0.16 USD and the consensus revenue estimate is 21.58M USD.
The next earnings revenue estimate has been revised downward by 18.49% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 121.5M 137.77% | 137.142M 12.87% | 60.881M -55.61% | 63.183M 3.78% | 134.87M 113.46% | |
| EBITDA YoY % growth | 1.63M 131.11% | 19.93M 1,122.67% | -40.617M -303.80% | -17.452M 57.03% | 4.016M 123.01% | |
| EBIT YoY % growth | 700K 111.67% | 18.865M 2,595.06% | -41.782M -321.48% | -24.903M 40.40% | 2.42M 109.72% | |
| Operating Margin | 0.58% | 13.76% | -68.63% | -39.41% | 1.79% | |
| EPS YoY % growth | -0.04 97.92% | 1.39 3,575.00% | -2.34 -268.35% | -1.30 44.42% | 0.06 104.31% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.16 84.00% | -0.05 87.92% | 0.00 100.00% | 0.03 108.27% | 0.11 168.75% |
| Revenue Q2Q % growth | 21.58M 124.86% | 26.828M 153.64% | 28.37M 146.31% | 36.492M 95.35% | 43.186M 100.12% |
| EBITDA Q2Q % growth | 1.246M 107.24% | -36.72K 99.50% | 689.01K 110.88% | 1.385M 122.05% | 2.03M 62.92% |
| EBIT Q2Q % growth | -3.105M 83.10% | -461.04K 93.92% | 264.69K 103.89% | 960.84K 113.82% | 2.626M 184.56% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
SURGEPAYS INC / SURG Forecast FAQ
Can you provide the upcoming earnings date for SURGEPAYS INC?
SURGEPAYS INC (SURG) will report earnings on 2026-03-23, after the market close.
What are the consensus estimates for SURG stock next earnings?
The consensus EPS estimate for the next earnings of SURGEPAYS INC (SURG) is -0.16 USD and the consensus revenue estimate is 21.58M USD.
What is the number of analysts for SURG stock?
The number of analysts covering SURGEPAYS INC (SURG) is 8.